Preclinical Trials Requests
The Mayo Clinic Pirnie Translational Polycystic Kidney Disease Center has long-standing expertise in conducting rodent preclinical trials (more than 30 in the last five years), which includes utilization and expertise in a range of rodent PKD models (hypomorphic and conditional), dosing regimens, drug delivery methods, phenotypic characterization, and statistical analysis. We also have ample expertise in testing compounds of interests in in vivo nematode and zebrafish models, in vitro cellular models, and ex vivo metanephric culture systems, all of which are more cost, space and time efficient, allowing relatively higher throughput screening of small molecules and potential therapeutics.
Given our extensive expertise, the Model Systems Core offers help to other researchers with preclinical trials needs.
Complete the online form to help us gain a better understanding of your interests and needs. After we review your request, we'll respond to inquiries within a week or so and initiate a teleconference to discuss the request.
Use this form to submit your request online.
Note: This form is not for patient use and should not be used to share any kind of patient information. Information you provide is used only to address your inquiry and not shared outside Mayo Clinic. Communication by email is not secure.
- Magenheimer BS, St John PL, Isom KS, Abrahamson DR, C De Lisle RC, Wallace DP, Maser RL, Grantham JJ, Calvet JP. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation. Journal of the American Society of Nephrology. 2006; doi:10.1681/ASN.2006030295.
- Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model. Journal of the American Society of Nephrology. 2015; doi:10.1681/ASN.2013121312.
- Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJM, Yu A, Grantham JJ, Li X. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. The Journal of Clinical Investigation. 2015; doi:10.1172/JCI80467.
- Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. Journal of the American Society of Nephrology. 2008; doi:10.1681/ASN.2007060688.